메뉴 건너뛰기




Volumn 44, Issue 2, 2010, Pages 302-310

Silodosin for benign prostatic hyperplasia

Author keywords

Benign prostatic hyperplasia; Silodosin

Indexed keywords

ALCOHOL; ALDEHYDE DEHYDROGENASE; ALFUZOSIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DILTIAZEM; DOXAZOSIN; ERYTHROMYCIN; FLUCONAZOLE; GLUCURONOSYLTRANSFERASE 2B7; GLYCOPROTEIN P; ITRACONAZOLE; KETOCONAZOLE; PLACEBO; PRAZOSIN; PROBENECID; RITONAVIR; SILDENAFIL; SILODOSIN; TADALAFIL; TAMSULOSIN; TERAZOSIN; VALPROIC ACID; VERAPAMIL;

EID: 76149126999     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M320     Document Type: Review
Times cited : (10)

References (35)
  • 1
    • 10244247679 scopus 로고    scopus 로고
    • Underdetection of clinical benign prostatic hyperplasia in a general medical practice
    • Collins MF, Friedman RH, Ash A, Hall R, Moskowitz MA. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med 1996;11:513-8.
    • (1996) J Gen Intern Med , vol.11 , pp. 513-518
    • Collins, M.F.1    Friedman, R.H.2    Ash, A.3    Hall, R.4    Moskowitz, M.A.5
  • 2
    • 0026841280 scopus 로고
    • Quantifying the smooth muscle content of the prostate using double-immuno-enzymatic staining and color assisted image analysis
    • Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immuno-enzymatic staining and color assisted image analysis. J Urol 1992;147:1167-70.
    • (1992) J Urol , vol.147 , pp. 1167-1170
    • Shapiro, E.1    Hartanto, V.2    Lepor, H.3
  • 3
    • 29244467960 scopus 로고    scopus 로고
    • Managing patients with lower urinary tract symptoms
    • DOI 10.1016/j.amjmed.2004.12.033
    • McNaughton-Collins M, Barry MJ. Managing patients with lower urinary tract symptoms. Am J Med 2005;118:1331-9. DOI 10.1016/j.amjmed.2004.12.033
    • (2005) Am J Med , vol.118 , pp. 1331-1339
    • McNaughton-Collins, M.1    Barry, M.J.2
  • 4
    • 0034692176 scopus 로고    scopus 로고
    • Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH)
    • DOI 10.1021/jm990567u
    • Meyer MD, Alteabach RJ, Basha FZ, et al. Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH). J Med Chem 2000; 43:1586-603. DOI 10.1021/jm990567u
    • (2000) J Med Chem , vol.43 , pp. 1586-1603
    • Meyer, M.D.1    Alteabach, R.J.2    Basha, F.Z.3
  • 5
    • 0029779304 scopus 로고    scopus 로고
    • Evaluation of the pharmacological selectivity profile of alpha-1-adrenoceptor antagonists at prostatic alpha-1-adrenoceptors: Binding, functional and in vivo studies
    • Kenny BA, Miller AM, Williamson IJ, et al. Evaluation of the pharmacological selectivity profile of alpha-1-adrenoceptor antagonists at prostatic alpha-1-adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 1996;118:871-8.
    • (1996) Br J Pharmacol , vol.118 , pp. 871-878
    • Kenny, B.A.1    Miller, A.M.2    Williamson, I.J.3
  • 6
    • 0030974958 scopus 로고    scopus 로고
    • Effects of tamsulosin metabolites at alpha-1-adrenoceptors subtypes
    • Taguchi K, Saitoh M, Sato S, et al. Effects of tamsulosin metabolites at alpha-1-adrenoceptors subtypes. J Pharmacol Exp Ther 1997;280:1-5.
    • (1997) J Pharmacol Exp Ther , vol.280 , pp. 1-5
    • Taguchi, K.1    Saitoh, M.2    Sato, S.3
  • 7
    • 0029155804 scopus 로고
    • KMD -3213, a novel, potent, alpha 1aadrenoceptor-selective antagonist: Characterization using recombinant human alpha 1-adrenoceptors and native tissues
    • Shibata K, Foglar R, Horie K, et al. KMD -3213, a novel, potent, alpha 1aadrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 1995;48: 250-8.
    • (1995) Mol Pharmacol , vol.48 , pp. 250-258
    • Shibata, K.1    Foglar, R.2    Horie, K.3
  • 8
    • 0036016946 scopus 로고    scopus 로고
    • α-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia
    • Thiyagarajan M. α-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. Pharmacology 2002;65:119-28.
    • (2002) Pharmacology , vol.65 , pp. 119-128
    • Thiyagarajan, M.1
  • 9
    • 76149102783 scopus 로고    scopus 로고
    • Product information. Rapaflo (silodosin). Corona, CA: Watson Pharmaceuticals, Inc., October 2008.
    • Product information. Rapaflo (silodosin). Corona, CA: Watson Pharmaceuticals, Inc., October 2008.
  • 10
    • 33749572713 scopus 로고    scopus 로고
    • 1A-adrenoreceptorselective antagonist for treating benign prostatic hyperplasia: results of a Phase III randomized, placebo controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24. DOI 10.1111/j.1464-410X.2006.06448.x
    • 1A-adrenoreceptorselective antagonist for treating benign prostatic hyperplasia: results of a Phase III randomized, placebo controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24. DOI 10.1111/j.1464-410X.2006.06448.x
  • 11
    • 54849405344 scopus 로고    scopus 로고
    • Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
    • DOI 10.1111/j.1442-2042.2008.02154.x
    • Takao T, Tsujimura A, Kiuchi H, et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 2008;15:992-6. DOI 10.1111/j.1442-2042.2008.02154.x
    • (2008) Int J Urol , vol.15 , pp. 992-996
    • Takao, T.1    Tsujimura, A.2    Kiuchi, H.3
  • 12
    • 67349102059 scopus 로고    scopus 로고
    • Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-40. Epub 16 Apr 2009. DOI 10.1016/j.juro.2009.02.034
    • Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-40. Epub 16 Apr 2009. DOI 10.1016/j.juro.2009.02.034
  • 13
    • 39549086056 scopus 로고    scopus 로고
    • 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007;16:1955-64. DOI 10.1517/13543784.16.12.1955
    • 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007;16:1955-64. DOI 10.1517/13543784.16.12.1955
  • 14
    • 33751019990 scopus 로고    scopus 로고
    • 1A-adrenoceptor antagonist silodosin (KMD -3213), a drug for the treatment of voiding dysfunction
    • 1A-adrenoceptor antagonist silodosin (KMD -3213), a drug for the treatment of voiding dysfunction. Arzneimittelforschung 2006;56:682-7.
    • (2006) Arzneimittelforschung , vol.56 , pp. 682-687
    • Tatemichi, S.1    Kiguchi, S.2    Kobayashi, M.3
  • 15
    • 54049121803 scopus 로고    scopus 로고
    • Ejaculatory dysfunction caused by the new alpha 1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography
    • DOI 10.1111/j.1442-2042.2008.02136.x
    • Nagai A, Hara R, Yokoyama T, Jo Y, Fujii T, Miyaji Y. Ejaculatory dysfunction caused by the new alpha 1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int J Urol 2008;15:915-8. DOI 10.1111/j.1442-2042.2008.02136.x
    • (2008) Int J Urol , vol.15 , pp. 915-918
    • Nagai, A.1    Hara, R.2    Yokoyama, T.3    Jo, Y.4    Fujii, T.5    Miyaji, Y.6
  • 16
    • 51349132022 scopus 로고    scopus 로고
    • Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers
    • Epub 9 Apr, DOI 10.1111/j.1743-6109.2008.00779.x
    • Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers. J Sex Med 2008;5:2185-90. Epub 9 Apr 2007. DOI 10.1111/j.1743-6109.2008.00779.x
    • (2007) J Sex Med 2008 , vol.5 , pp. 2185-2190
    • Kobayashi, K.1    Masumori, N.2    Hisasue, S.3
  • 17
    • 19344367714 scopus 로고    scopus 로고
    • Intraoperative floppy iris syndrome associated with tamsulosin
    • DOI 10.1016/j.jcrs.2005.02.027
    • Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664-73. DOI 10.1016/j.jcrs.2005.02.027
    • (2005) J Cataract Refract Surg , vol.31 , pp. 664-673
    • Chang, D.F.1    Campbell, J.R.2
  • 20
    • 0032991607 scopus 로고    scopus 로고
    • A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
    • Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
    • (1999) Eur Urol , vol.36 , pp. 1-13
    • Djavan, B.1    Marberger, M.2
  • 21
    • 0037347577 scopus 로고    scopus 로고
    • Effect of terazosin on clinical benign prostatic hyperplasia in older adults
    • Mudiyala R, Ahmed A. Effect of terazosin on clinical benign prostatic hyperplasia in older adults. J Am Geriatr Soc 2003;51:424-6.
    • (2003) J Am Geriatr Soc , vol.51 , pp. 424-426
    • Mudiyala, R.1    Ahmed, A.2
  • 22
    • 11844264906 scopus 로고    scopus 로고
    • Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia - related lower urinary tract symptoms
    • DOI 10.1016/j.clinthera.2004.11.006
    • Lowe FC. Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia - related lower urinary tract symptoms. Clin Ther 2004;26:1701-13. DOI 10.1016/j.clinthera.2004.11.006
    • (2004) Clin Ther , vol.26 , pp. 1701-1713
    • Lowe, F.C.1
  • 23
    • 10644274279 scopus 로고    scopus 로고
    • State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
    • DOI 10.1016/j.urology.2004.07.031
    • Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8. DOI 10.1016/j.urology.2004.07.031
    • (2004) Urology , vol.64 , pp. 1081-1088
    • Djavan, B.1    Chapple, C.2    Milani, S.3
  • 24
    • 84868172448 scopus 로고    scopus 로고
    • accessed 2010 Jan 20
    • Drugstore.com. http://drugstore.com (accessed 2010 Jan 20).
  • 25
    • 0031774517 scopus 로고    scopus 로고
    • A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
    • DOI 10.1159/000019639
    • de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998;33:481-8. DOI 10.1159/000019639
    • (1998) Eur Urol , vol.33 , pp. 481-488
    • de Mey, C.1    Michel, M.C.2    McEwen, J.3    Moreland, T.4
  • 26
    • 51349088548 scopus 로고    scopus 로고
    • A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia
    • Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547-59.
    • (2008) Int J Clin Pract , vol.62 , pp. 1547-1559
    • Nickel, J.C.1    Sander, S.2    Moon, T.D.3
  • 27
    • 34249977256 scopus 로고    scopus 로고
    • Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: A randomized, placebo-controlled trial
    • Resnick MI, Roehrborn CG. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. Prostate Cancer Prostatic Dis 2007;10:155-9.
    • (2007) Prostate Cancer Prostatic Dis , vol.10 , pp. 155-159
    • Resnick, M.I.1    Roehrborn, C.G.2
  • 28
    • 0032100513 scopus 로고    scopus 로고
    • Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group
    • DOI 10.1016/S0090-4295(98)00126-5
    • Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900. DOI 10.1016/S0090-4295(98)00126-5
    • (1998) Urology , vol.51 , pp. 892-900
    • Lepor, H.1
  • 29
    • 33644827913 scopus 로고    scopus 로고
    • ALF-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: A 2-year experience in 'real-life' practice
    • DOI 10.1111/j.1464-410X.2005.05962. x
    • Elhilali M, Emberton M, Matzkin H, et al.; ALF-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2006;97:513-9. DOI 10.1111/j.1464-410X.2005.05962. x
    • (2006) BJU Int , vol.97 , pp. 513-519
    • Elhilali, M.1    Emberton, M.2    Matzkin, H.3
  • 30
    • 8544265325 scopus 로고    scopus 로고
    • Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia
    • DOI 10.1111/j.1442-2042.2004.00913.x
    • Ichioka K, Ohara H, Terada N, et al. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int J Urol 2004;11:870-5. DOI 10.1111/j.1442-2042.2004.00913.x
    • (2004) Int J Urol , vol.11 , pp. 870-875
    • Ichioka, K.1    Ohara, H.2    Terada, N.3
  • 31
    • 4644351244 scopus 로고    scopus 로고
    • Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): First-year follow-up report
    • Palacio A, Hernández C, Marqués A, Prats J, Espinosa FJ. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report. Arch Esp Urol 2004;57:451-60.
    • (2004) Arch Esp Urol , vol.57 , pp. 451-460
    • Palacio, A.1    Hernández, C.2    Marqués, A.3    Prats, J.4    Espinosa, F.J.5
  • 32
    • 10344223529 scopus 로고    scopus 로고
    • Intermittent tamsulosin therapy in men with lower urinary tract symptoms
    • Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D. Intermittent tamsulosin therapy in men with lower urinary tract symptoms. J Urol 2005;173:155-7.
    • (2005) J Urol , vol.173 , pp. 155-157
    • Yanardag, H.1    Goktas, S.2    Kibar, Y.3    Kilic, S.4    Erduran, D.5
  • 33
    • 38849201263 scopus 로고    scopus 로고
    • Roehrborn CG, Siami P, Barkin J, et al.; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-21. Epub 21 Dec 2007. DOI 10.1016/j.juro.2007.09.084
    • Roehrborn CG, Siami P, Barkin J, et al.; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-21. Epub 21 Dec 2007. DOI 10.1016/j.juro.2007.09.084
  • 34
    • 62149096763 scopus 로고    scopus 로고
    • Barkin J, Roehrborn CG, Siami P, et al.; CombAT Study Group. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009;103:919-26. Epub 23 Feb 2009. DOI 10.1111/j.1464-410X.2009.08196.x
    • Barkin J, Roehrborn CG, Siami P, et al.; CombAT Study Group. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009;103:919-26. Epub 23 Feb 2009. DOI 10.1111/j.1464-410X.2009.08196.x
  • 35
    • 0347882750 scopus 로고    scopus 로고
    • Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    • DOI 10.1056/NEJMoa030656
    • McConnell JD, Roehrborn CG, Bautista OM, et al.; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98. DOI 10.1056/NEJMoa030656
    • (2003) N Engl J Med , vol.349 , pp. 2387-2398
    • McConnell, J.D.1    Roehrborn, C.G.2    Bautista, O.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.